沙美特罗替卡松气雾剂在慢阻肺呼吸衰竭患者中的应用效果

Application Effect of Salmeterol Xinafoate and Fluticasone Propionate Aerosol in the Patients with Respiratory Failure Caused by COPD

目的:探究及分析沙美特罗替卡松气雾剂在慢阻肺(COPD)呼吸衰竭患者中的应用效果。方法:将2019年7月-2022年1月龙岩市第二医院收治的94例慢阻肺呼吸衰竭患者根据随机数字表法分为对照组和观察组,各47例。对照组进行常规慢阻肺呼吸衰竭治疗,观察组则在对照组的基础上加用沙美特罗替卡松气雾剂。比较两组的总有效率、不良反应发生率、治疗前后的血气分析指标[动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))及pH值]及气体交换指标[肺换气指标最大吸气压(PImax)及最大呼气压(PEmax)、呼吸系统顺应性(Cst)及气道阻力(Raw)]。结果:观察组的治疗总有效率显著高于对照组,差异有统计学意义(P<0.05);两组的不良反应发生率比较,差异无统计学意义(P>0.05);治疗前两组的血气分析指标、肺换气指标、Cst及Raw比较,差异无统计学意义(P>0.05),治疗2、7 d后两组的血气分析指标、肺换气指标、Cst及Raw均显著改善,且观察组均显著优于对照组,差异有统计学意义(P<0.05)。结论:沙美特罗替卡松气雾剂在慢阻肺呼吸衰竭患者中的应用效果较好,且可显著改善患者的气体交换状态,应用价值相对较高。

Objective:To investigate and analyze the application effect of Salmeterol Xinafoate and Fluticasone Propionate Aerosol in the patients with respiratory failure caused by chronic obstructive pulmonary disease (COPD).Method:A total of 94 patients with respiratory failure caused by COPD admitted to Longyan Second Hospital from July 2019 to January 2022 were divided into control group and observation group by the method of random number table,47 cases in each group.The control group were treated with routine treatment for respiratory failure caused by COPD,the observation group were treated with Salmeterol Xinafoate and Fluticasone Propionate Aerosol on the basis of control group.Then the total effective rates,adverse reactions rates,blood gas analysis indexes[partial pressure of arterial blood oxygen (PaO_(2)),partial pressure of arterial blood carbon dioxide (PaCO_(2)) and pH]and gas exchange indexes[pulmonary ventilation indexes included maximum inspiratory pressure (PImax) and maximum expiratory pressure (PEmax),respiratory system compliance (Cst) and airway resistance (Raw)]before and after the treatment of two groups were compared.Result:The total effective rate in the observation group was significantly higher than that in the control group,the difference was statistically significant (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).There were no significant differences in the blood gas analysis indexes,pulmonary ventilation indexes,Cst and Raw of two groups before the treatment (P>0.05).After 2,7 days of treatment,the blood gas analysis index,lung ventilation index,Cst and Raw in the two groups were significantly improved,and the observation group were significantly better than those in the control group,the differences were statistically significant (P<0.05).Conclusion:The application effect of Salmeterol Xinafoate and Fluticasone Propionate Aerosol in the patients with respiratory failure caused by COPD is better,and it can significantly improve the gas exchange state,so its application value is higher.